Alright, this is one among only a few potential big movers in biotech that is safe to play - legit company with a revolutionary cancer drug, that has a real PT of $25 EOY and PT $200 if they get acquired and that's what we are hoping for. It is sitting just below $11 at the moment.Technical analysis: MACD triggering bullish crossover and above average volume on the daily.Fundamental analysis:
- Easy acquisition for $AMGN $VTRS $RHHBY compliments G-CSF sales $8B combined globally, and is I/O target off the radar, enhances dendritic cells, mobilizes CD34+
- Plinabulin used to treat the highest risk chemotherapy patients in the US is a market of 225,000 people, and with at least 3-5 cycles per chemo treatment that's 675K to 1.1M doses of Plinabulin
- Plinabulin is used in combination with G-CSFs which sell a combined $5B in the USA and $8B globally every year. It's a perfect buyout target for a G-CSF selling pharma company to enhance their sales and maximize their sales force such as $AMGN, $VRTS, $RHHBY
- Increasing patient quality of life, and reducing risk of neutropenia, Plinabulin gives patients the highest probability for survival by continuing their chemotherapy regimen at the maximum dose and duration.
- Febrile and Profound Neutropenia patients are treated with G-CSFs that cause the bone marrow to release white blood cells, but also cause severe bone pain in patients. Plinabulin effectively, almost, eradicates this bone pain.
- If you check the ownership structure, you'll it is positioned to dominate US and China.
- Recently raised $75m, overall analyst ratings is BUY
The amazing news is they have announced their drug is not only very effective in treating cancer, is safe and reduces bone pain but also increases chance of survival of colon cancer, liver cancer and other patients.https://www.beyondspringpharma.com/pressreleases/info.aspx?itemid=4252BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring’s lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatmentof non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation toplinabulin for concurrent administration with myelosuppressive chemotherapeuticregimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN).Institutional ownership: https://fintel.io/so/us/bysi
$BYSI is the next GLSI very soon if we are lucky.
Submitted December 10, 2020 at 11:24PM by DrHumorous https://ift.tt/39WSphr
